Study of the safety, tolerability, pharmacokinetics and immunogenicity of REGN-668 administered subcutaneously to healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2012
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Adverse reactions
- 12 Mar 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2011 New trial record